Bone marrow-derived stem cell (BMSC)

Allogeneic bone marrow-derived stem cells are a population of multipotent cells, including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), harvested from a genetically non-identical donor. HSCs are primarily used in transplantation to replace a recipient's diseased or depleted bone marrow, facilitating the production of new, healthy blood and immune cells (NIH, 2023). MSCs are increasingly utilized for their potent immunomodulatory and regenerative properties, as they can migrate to sites of inflammation and secrete factors that modulate the activity of T-cells and macrophages (Nature Reviews, 2018). Unlike traditional molecular targets, these cells serve as a dynamic therapeutic modality that interacts with the host microenvironment to restore homeostasis and repair tissue damage (PubMed: 31273033). Clinical use requires careful Human Leukocyte Antigen (HLA) matching to mitigate the risk of Graft-versus-Host Disease (GvHD), where donor immune cells recognize the host as foreign and initiate an inflammatory attack (StatPearls, 2023).

Other names

Allogeneic bone marrow-derived stem cellBone marrow stem cellMarrow-derived stem cellAllogeneic BMSCAllogeneic hematopoietic stem cellAllogeneic mesenchymal stem cell

Allogeneic bone marrow-derived stem cells function as therapeutic agents through two primary pathways: hematopoietic reconstitution and immunomodulation. Hematopoietic stem cells (HSCs) migrate to the bone marrow niche to differentiate into all blood lineages, restoring immune and circulatory function in patients with hematological malignancies or marrow failure (NIH, 2023). Mesenchymal stem cells (MSCs) act primarily via paracrine signaling, secreting anti-inflammatory cytokines, growth factors, and extracellular vesicles that suppress pathogenic T-cell responses and promote endogenous tissue regeneration (Nature Reviews Rheumatology, 2015; PubMed: 28543322).